Substance Use Disorder (SUD) Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | Acadia Healthcare, Amygdala, JourneyPure, Kinoxis, PursueCare, Virtual Rehab, Workit Health, Zpharm, Pyramid Healthcare

DelveInsight's "Substance Use Disorder Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the Substance Use Disorder market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Additionally, the report delves into emerging therapies for Substance Use Disorder, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for Substance Use Disorder, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of Substance Use Disorder management.

Learn How the Substance Use Disorder Market is Evolving with the Ongoing Developments @ Substance Use Disorder Market Outlook 

Substance Use Disorder: An Overview

Substance use disorder (SUD), also called Drug addiction, is a condition when a person's use of alcohol and/or drug substances leads to impairment, such as health problems, disability, or problems at work, school, or home. Addiction represents the most severe form of this disorder.

The exact cause of substance use disorder is not known. A person's genes, the action of the drug, peer pressure, emotional distress, anxiety, depression, and environmental stress can all be factors. Many who develop a substance use problem have depression, attention deficit disorder, post-traumatic stress disorder, or another mental problem. A stressful or chaotic lifestyle and low self-esteem are also common.

Commonly used substances include Opiates and other narcotics, stimulants (amphetamines), depressants (alcohol, barbiturates, benzodiazepines (Ativan, Xanax), chloral hydrate, and paraldehyde), LSD, mescaline, marijuana (hashish), psilocybin ("mushrooms"), and phencyclidine (PCP, or "angel dust").

Substance Use Disorder is a serious condition, and it is not easy to treat. The best care and treatment involve trained professionals. Treatment starts by recognizing the problem. Although denial can be a common symptom of addiction, those who are addicted will have less denial if they are treated with respect, rather than being told what to do. The substance can be slowly withdrawn or stopped immediately. Support of physical or emotional symptoms, as well as staying drug-free, are key to treatment.

Substance Use Disorder Market Key Facts

• According to the American Addiction Centers, in 2017, approximately four percent of the American adolescent population aged 12-17 suffered from a substance use disorder. About 1.8% of adolescents had an alcohol use disorder, and about three percent of this population suffered from an illicit drug use disorder.
• As per the study by Carney et al. (2020), alcohol abuse was the most common lifetime Substance Use Disorder diagnosis (9.3%), followed by alcohol dependence (7.3%) and drug abuse.
• According to the study conducted by Polak et al., (2015), titled “Gender Considerations in Addiction: Implications for Treatment,” gender differences exist in the development, course, and treatment of substance use disorders. Men are 1.9–2.2 times more likely to have Substance Use Disorder, women are more vulnerable to negative medical and psychosocial consequences of alcohol and other drugs.

Get Exclusive Data and Key Insights Shaping the Market Dynamics @ Substance Use Disorder Market Trends

Substance Use Disorder Therapeutics Analysis

Treatment generally begins with recognizing the problem. Though denial is a common symptom of addiction, people who are addicted have far less denial if they are treated with empathy and respect, rather than told what to do or being confronted.

The substance may either be slowly withdrawn or stopped abruptly. Support for physical and emotional symptoms, as well as staying drug-free (abstinence) are also key to treatment. People with drug overdose may need emergency treatment in the hospital. The exact treatment depends on the drug used. 

Detoxification (detox) is the withdrawal of the substance abruptly in an environment where there is good support. Detoxification can be done on an inpatient or outpatient basis. At times, another drug with a similar action or effect on the body is taken, as the dose is slowly decreased to reduce the side effects and risks of withdrawal. For example, for narcotic addiction, methadone or similar drugs may be used to prevent withdrawal and continued use.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Substance Use Disorder. Currently, Omeros Corp. is leading the therapeutics market with its Substance Use Disorder drug candidates in the most advanced stage of clinical development.

Substance Use Disorder Therapeutic Advancements and Emerging Treatments:

• Substance Use Disorder Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Acadia Healthcare, Amygdala Neurosciences, Asana Recovery, JourneyPure, Kinoxis Therapeutic, Promises Behavioral Health, PursueCare, Pyramid Healthcare, Virtual Rehab, Workit Health, Zpharm, and others, are actively engaged in developing novel drugs for potential market entry.
• Substance Use Disorder Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Substance Use Disorder. Some of the emerging therapies in the pipeline include reSET (Pear Therapeutics), Ibudilast (MN-166) (MediciNova), OMS405 (Omeros Corp.), IXT-m200 (InterveXion Therapeutics), and many others.

Key Developments in the Substance Use Disorder Market

• Recently in May 2020, Pear Therapeutics, launched the PEAR Assistance Program to ensure eligible patients living with Substance Use Disorder or Opioid Use Disorder have access to FDA-authorized prescription digital therapeutics (PDTs) for addiction treatment.
• In November 2018, Sandoz, and Pear Therapeutics, commercially launched reSET for patients with Substance Use Disorder. reSET, the first and only FDA-authorized prescription digital therapeutic, is immediately available.

Discover Significant Progress and Start Making Informed Decisions @ Clinical, Commercial, and Regulatory Activities in the Substance Use Disorder Market

Substance Use Disorder Market Growth Factors and Associated Trends

Substance Use Disorder in the 7MM (Seven Major Markets) faces a complex interplay of drivers and barriers influencing its market dynamics. Several drivers contribute to the growth and evolution of the Substance Use Disorder market. Firstly, increased awareness and destigmatization of mental health issues have encouraged more individuals to seek help for Substance Use Disorder, thereby expanding the patient pool. Additionally, advancements in research and development have led to the emergence of innovative therapies and medications, offering more effective treatment options. Moreover, supportive government initiatives and healthcare policies aimed at improving access to addiction treatment services have played a pivotal role in addressing Substance Use Disorder.

However, the Substance Use Disorder market also encounters significant barriers that impede its progress. One of the foremost challenges is the stigma associated with addiction, which often discourages individuals from seeking treatment and contributes to social isolation. Furthermore, the high cost of some treatment modalities, coupled with limited insurance coverage for certain therapies, restricts access for many patients. Regulatory hurdles, such as stringent approval processes for new drugs and therapies, also pose challenges for companies aiming to introduce novel treatments in the market. Moreover, the lack of standardized protocols and varying treatment efficacy across different regions further complicates the landscape, making it challenging to implement universal strategies for managing Substance Use Disorder.

In navigating these complex dynamics, stakeholders in the Substance Use Disorder market must collaborate to address barriers, innovate treatment approaches, and advocate for policies that enhance accessibility and affordability while continuing to raise awareness and reduce stigma around substance use disorders.

Substance Use Disorder Market

The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for Substance Use Disorder. Moreover, it conducts a thorough evaluation of the factors driving and hindering the Substance Use Disorder market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.

The report meticulously outlines the market trends concerning each marketed Substance Use Disorder drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.

Discover the Anticipated Evolution and Growth of the Market @ Substance Use Disorder Therapeutics Market Forecast

Substance Use Disorder Epidemiology Assessment

The epidemiology section offers valuable insights into the historical, present, and anticipated trends in Substance Use Disorder epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected Substance Use Disorder epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.

The Report Covers the Substance Use Disorder Epidemiology, Segmented as -

• Total Prevalent Cases of Substance Use Disorder in the 7MM (2019-2032)
• Severity-specific Prevalent Cases of Substance Use Disorder in the 7MM (2019-2032)
• Diagnosed and Treatable Cases of Substance Use Disorder in the 7MM (2019-2032)
• Age-specific Prevalent Cases of Substance Use Disorder (e.g., adolescents and adults) in the 7MM (2019-2032)
• Prevalent Cases of Substance Use Disorder based on substance type (e.g., alcohol, illicit drugs, or both) in the 7MM (2019-2032)
• Gender-specific Prevalent Cases of Substance Use Disorder in the 7MM (2019-2032)

Substance Use Disorder Drugs Uptake and Pipeline Development Activities

The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the Substance Use Disorder market during the study period. This analysis encompasses the assessment of drug uptake in the Substance Use Disorder market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among Substance Use Disorder drugs, considering their sales performance and respective market shares.

The report encompasses comprehensive coverage of ongoing Substance Use Disorder pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for Substance Use Disorder. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.

Reports Key Features and Analysis

• Study Period - 2019-32
• Forecast Period - 2023-32
• Geography Coverage - 7MM (United States, EU4 [Germany, Spain, Italy, France], the United Kingdom, and Japan)
• Market Size (by 2032) and Expected CAGR - Download the Sample PDF
• Major Players Shaping the Market Dynamics - Acadia Healthcare, Amygdala Neurosciences, Asana Recovery, JourneyPure, Kinoxis Therapeutic, Promises Behavioral Health, PursueCare, Pyramid Healthcare, Virtual Rehab, Workit Health, Zpharm, and many others.
• Emerging and Marketed Therapies Covered in the Report - reSET (Pear Therapeutics), Ibudilast (MN-166) (MediciNova), OMS405 (Omeros Corp.), IXT-m200 (InterveXion Therapeutics), and many others.

For In-depth Insights, key Report Offerings TOC, Access the Sample PDF File @ Substance Use Disorder Therapeutics Market Outlook and Forecast

Related Reports:

• Substance Use Disorder Pipeline Insight

The Substance Use Disorder Pipeline Insight report provides comprehensive insights about major pharma and biotech companies and emerging drugs in the Substance Use Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Healthcare Consulting and Market Research Services by DelveInsight

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services

Explore Our Success Story on Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study!

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

 Contact Information:

Shruti Thakur (Manager, Marketing and IB)

info@delveinsight.com

www.delveinsight.com

Connect with DelveInsight: LinkedIn | Facebook | Twitter